Related Experiment Video
Updated: Jan 28, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
Patrick R Halliday1,2, Collin M Blakely1,2, Trever G Bivona3,4
1Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.
Purpose Of Review:
Lung cancer remains the leading cause of cancer-related mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) has led to the discovery of actionable oncogenic driver alterations, which has revolutionized treatment for this disease. This review will move beyond traditional mutational drivers such as EGFR and ALK and will instead focus on emerging targets and the efficacy of new precision therapies.
Recent Findings:
Here, we discuss both established and emerging targeted therapy approaches, as well as ongoing challenges for the treatment of NSCLC patients harboring oncogenic alterations of the following types-gene fusions (ROS1, RET, NTRK), receptor tyrosine kinases (MET amplification and exon 14 mutations and EGFR/HER2 exon 20 insertion mutations), and MAPK signaling (SHP2 and altered BRAF and NF1). The treatment of lung cancer is increasingly biomarker-driven, as patients are selected for targeted agents based on the identification of genetic alterations amenable to inhibition. Our ability to further improve patient outcomes with this precision medicine approach will require continued efforts to identify, characterize, and target lesions driving lung cancer tumorigenesis and progression.
Insights
This review covers emerging targeted therapies for non-small cell lung cancer (NSCLC), focusing on genetic alterations beyond EGFR and ALK. Precision medicine advances offer new hope for improved patient outcomes in lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer is a leading cause of global cancer mortality.
- Genetic profiling has identified actionable oncogenic drivers in non-small cell lung cancer (NSCLC).
- This has revolutionized treatment strategies, shifting towards precision medicine.
Purpose of the Study:
- To review emerging targets and precision therapies for NSCLC.
- To discuss established and novel targeted approaches for NSCLC with specific genetic alterations.
- To highlight ongoing challenges in the precision treatment of lung cancer.
Main Methods:
- Review of current literature on targeted therapies for NSCLC.
- Focus on gene fusions (ROS1, RET, NTRK), receptor tyrosine kinases (MET, EGFR/HER2), and MAPK signaling alterations (SHP2, BRAF, NF1).
- Discussion of biomarker-driven treatment selection.
Main Results:
- Emerging targets include ROS1, RET, NTRK gene fusions, MET alterations, EGFR/HER2 exon 20 insertions, and MAPK signaling pathway aberrations.
- Targeted therapies are increasingly selected based on specific genetic alterations.
- Significant progress has been made in developing precision therapies for NSCLC.
Conclusions:
- Precision medicine, guided by molecular profiling, is transforming NSCLC treatment.
- Continued research is crucial to identify and target novel drivers of lung cancer.
- Further efforts are needed to optimize patient outcomes through advanced targeted therapies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Emerging Adulthood
Gene Therapy
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

